ElieTraerMD

Oncology • Portland, OR

OHSU

Join to view full profile

Dr. Traer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Traer's full profile

Already have an account?

Office
3181 SW Sam Jackson Park Road, 2nd Floor, Portland, OR
Portland, OR 97239
Phone+1 503-494-5058

Education & Training

Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2006 - 2009
University of Texas Southwestern Medical SchoolClass of 2006
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology

Certifications & Licensure

OR State Medical License 2009 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2021 Jan 14
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of TAS1440 With ATRA in Subjects With r/r AML Start of enrollment: 2020 Mar 15
Active, not recruiting
Phase 1
Roles: Contact
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact

Publications & Presentations

PubMed

1 citations
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Fieke W Hoff, William G Blum, Ying Huang, Rina Li Welkie, Ronan T Swords
Blood Advances. 2024-10-22
Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia.
Hong De Sa, Thomas Deloughery, Andy Kaempf, Curtis Lachowiez, Jessica Leonard
Leukemia & Lymphoma. 2024-09-18
3 citations
Menin Inhibition With Revumenib for-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano
Journal of Clinical Oncology. 2024-08-09

Abstracts/Posters

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Elie Traer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018